The Evolution of Reverse Payment Cases: Courts and Agencies’ Approaches in Pharma Litigation
In a recent Insight article published by Global Competition Review, legal experts from Lowenstein Sandler LLP delve into the status […]
In a recent Insight article published by Global Competition Review, legal experts from Lowenstein Sandler LLP delve into the status […]
In the world of prescription drugs, brand-name manufacturers have employed various strategies to maintain revenue streams in the face of
A review article in the Journal of Pharmaceutical Sciences analyzes the trends in drug repurposing through the 505(b)(2) pathway, as
Here’s a summary of a new article that used DrugPatentWatch data: NIH Funding for Patents That Contribute to Market Exclusivity
While answering a question for a DrugPatentWatch user, the question arose of technologies the NIH has licensed. It turns out
In a recent article published by IAM Magazine, titled “Why Pharma Companies Should File Patents Later In The R&D Process,”
DrugChatter recently launched as an experimental AI chat-based business intelligence tool. Here’s some of the more interesting questions it’s been
Introducing DrugChatter.com: Empowering Access to Biopharmaceutical Drug Insights through AI Chat We are pleased to introduce DrugChatter.com, a groundbreaking platform
DrugChatter.com: AI Chat for Biopharmaceutical Drug Insights Read Post »
On NPR’s All Things Considered, Sydney Lupkin asked DrugPatentWatch if drug patents could be used to identify injector pens which
NPR and DrugPatentWatch – Can drug injector pens be swapped? Read Post »